Compare CXDO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | CHRS |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 209.8M |
| IPO Year | 1999 | 2014 |
| Metric | CXDO | CHRS |
|---|---|---|
| Price | $6.91 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $9.20 | $5.51 |
| AVG Volume (30 Days) | 457.0K | ★ 700.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 166.67 | ★ 472.00 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $68,167,000.00 | N/A |
| Revenue This Year | $45.26 | $73.08 |
| Revenue Next Year | $13.31 | $30.94 |
| P/E Ratio | $340.50 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.26 | $0.81 |
| 52 Week High | $11.23 | $2.62 |
| Indicator | CXDO | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 45.98 |
| Support Level | $6.54 | $1.38 |
| Resistance Level | $7.02 | $1.74 |
| Average True Range (ATR) | 0.44 | 0.06 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 40.46 | 47.63 |
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.